Faster global financial news!
Eli Lilly
-
Eli Lilly's new obesity drug delivers 23.3% weight loss in Type 2 diabetes patients
Eli Lilly's experimental drug eloralintide, when combined with Zepbound, achieved an average weight loss of 23.3% over approximately 11 months in patients with Type 2 diabetes. This compares to 14.8%
-
China's InnoCare Pharma and US pharmaceutical giant Eli Lilly enter strategic research collaboration and licensing agreement potentially worth up to US$3.35 billion.
China's InnoCare Pharma and US pharmaceutical giant Eli Lilly enter strategic research collaboration and licensing agreement potentially worth up to US$3.35 billion.
-
Novo Nordisk unveils new growth strategy, but analysts remain skeptical about the market prospects of its GLP-1 drugs.
Novo Nordisk unveiled a strategy this week aimed at revitalizing growth, planning to diversify its product pipeline to drive expansion after the patents for its blockbuster drugs Wegovy and Ozempic ex
-
Eli Lilly CEO Dave Ricks says 700,000 new seniors have started GLP-1s since Medicare coverage launched in July, with 70% on Lilly drugs
Ricks told CNBC on Monday that the rollout of Medicare coverage for obesity drugs has been "very encouraging," expanding the broader GLP-1 market as hoped. The coverage is provided through a temporary
-
Eli Lilly to acquire Merida Biosciences for up to $2.88 billion, expanding into autoimmune diseases beyond obesity drugs
Eli Lilly agreed to acquire Merida Biosciences for up to $2.88 billion in cash, a move aimed at diversifying its pipeline into autoimmune diseases. The deal, expected to close in Q4 2026, will help Li
-
Yahoo Finance analysis favors Eli Lilly over AbbVie for 2026 healthcare stock investment
Yahoo Finance analysis suggests Eli Lilly and Co (LLY) is a better healthcare stock buy for 2026 compared to AbbVie Inc (ABBV), citing Eli Lilly's strong growth in metabolic and obesity platforms driv
-
Analysis indicates that Eli Lilly and Company's (LLY) second-quarter revenue increased by 48% year-over-year, with its stock price recently reaching $1280, leading to market attention on the possibility of a stock split.
The article analyzes that Eli Lilly's stock price recently reached $1280 per share, with its last stock split occurring nearly 30 years ago in October 1997. Although stock splits typically do not chan
-
Investor's Business Daily: Eli Lilly (LLY) Stock Nears New Buy Point After Strong QTR Earnings, Selected To IBD 50 Growth Stocks To Watch List
Investor's Business Daily: Eli Lilly (LLY) Stock Nears New Buy Point After Strong QTR Earnings, Selected To IBD 50 Growth Stocks To Watch List
-
Dow Jones stock index futures rose, while SpaceX and AMD shares fell, and Arista and Eli Lilly shares rose, with the S&P 500 index remaining at a high level.
Dow Jones stock index futures rose, while SpaceX and AMD shares fell, and Arista and Eli Lilly shares rose, with the S&P 500 index remaining at a high level.
-
Eli Lilly's stock is seen as ripe for a split after its obesity drug-fueled rally pushed shares consistently above $1,000
Eli Lilly's stock is seen as ripe for a split after its obesity drug-fueled rally pushed shares consistently above $1,000
-
Analysis: Novo Nordisk's New Weight-Loss Drugs Face Efficacy Challenges Against Eli Lilly
A recent analysis indicates that Novo Nordisk's stock has fallen 29% over the past 12 months, as its new weight-loss drug candidates face stiff competition from Eli Lilly. Novo Nordisk's CagriSema, a
-
Eli Lilly's new obesity drug delivers 23.3% weight loss in Type 2 diabetes patients
Eli Lilly's experimental drug eloralintide, when combined with Zepbound, achieved an average weight loss of 23.3% over approximately 11 months in patients with Type 2 diabetes. This compares to 14.8%
-
China's InnoCare Pharma and US pharmaceutical giant Eli Lilly enter strategic research collaboration and licensing agreement potentially worth up to US$3.35 billion.
China's InnoCare Pharma and US pharmaceutical giant Eli Lilly enter strategic research collaboration and licensing agreement potentially worth up to US$3.35 billion.
-
Novo Nordisk unveils new growth strategy, but analysts remain skeptical about the market prospects of its GLP-1 drugs.
Novo Nordisk unveiled a strategy this week aimed at revitalizing growth, planning to diversify its product pipeline to drive expansion after the patents for its blockbuster drugs Wegovy and Ozempic ex
-
Eli Lilly CEO Dave Ricks says 700,000 new seniors have started GLP-1s since Medicare coverage launched in July, with 70% on Lilly drugs
Ricks told CNBC on Monday that the rollout of Medicare coverage for obesity drugs has been "very encouraging," expanding the broader GLP-1 market as hoped. The coverage is provided through a temporary
-
Eli Lilly to acquire Merida Biosciences for up to $2.88 billion, expanding into autoimmune diseases beyond obesity drugs
Eli Lilly agreed to acquire Merida Biosciences for up to $2.88 billion in cash, a move aimed at diversifying its pipeline into autoimmune diseases. The deal, expected to close in Q4 2026, will help Li
-
Yahoo Finance analysis favors Eli Lilly over AbbVie for 2026 healthcare stock investment
Yahoo Finance analysis suggests Eli Lilly and Co (LLY) is a better healthcare stock buy for 2026 compared to AbbVie Inc (ABBV), citing Eli Lilly's strong growth in metabolic and obesity platforms driv
-
Analysis indicates that Eli Lilly and Company's (LLY) second-quarter revenue increased by 48% year-over-year, with its stock price recently reaching $1280, leading to market attention on the possibility of a stock split.
The article analyzes that Eli Lilly's stock price recently reached $1280 per share, with its last stock split occurring nearly 30 years ago in October 1997. Although stock splits typically do not chan
-
Investor's Business Daily: Eli Lilly (LLY) Stock Nears New Buy Point After Strong QTR Earnings, Selected To IBD 50 Growth Stocks To Watch List
Investor's Business Daily: Eli Lilly (LLY) Stock Nears New Buy Point After Strong QTR Earnings, Selected To IBD 50 Growth Stocks To Watch List
-
Dow Jones stock index futures rose, while SpaceX and AMD shares fell, and Arista and Eli Lilly shares rose, with the S&P 500 index remaining at a high level.
Dow Jones stock index futures rose, while SpaceX and AMD shares fell, and Arista and Eli Lilly shares rose, with the S&P 500 index remaining at a high level.
-
Eli Lilly's stock is seen as ripe for a split after its obesity drug-fueled rally pushed shares consistently above $1,000
Eli Lilly's stock is seen as ripe for a split after its obesity drug-fueled rally pushed shares consistently above $1,000
-
Analysis: Novo Nordisk's New Weight-Loss Drugs Face Efficacy Challenges Against Eli Lilly
A recent analysis indicates that Novo Nordisk's stock has fallen 29% over the past 12 months, as its new weight-loss drug candidates face stiff competition from Eli Lilly. Novo Nordisk's CagriSema, a
- No data
Eli Lilly
24H Trending
-
1
What is FLOW? An Analysis of the Flow Blockchain Ecosystem and Its Current Status
-
2
Report: Hedge Funds Exit Bitcoin ETF Arbitrage Trades, Sovereign Wealth Funds and Retail Investors Step In
-
3
LS Cable subsidiary Gaon Cable secures W120b ($90m) US AI data center cable deal
-
4
Iranian President Pezeshkian stated that Iran is ready to expand cooperation with Turkey to serve common interests and enhance regional security.
-
5
Global Business Forum Urges Business Leaders to Embrace AI and Rethink Strategies
-
6
Unlimit founder backs Phase blockchain with $45M as mainnet launches
-
7
Google and Microsoft's Q3 capital expenditure falls short of estimates, raising concerns about AI build-out costs and delays
-
8
Iran's Islamic Revolutionary Guard Corps claims to have shot down a US-made MQ-1 drone near the Strait of Hormuz.
-
9
Event prediction platform Kalshi completes $1 billion funding round, reaching a valuation of $40 billion, with non-sports revenue run rate exceeding $1 billion.
-
10
New ECB staff estimates show bond yield rise cutting 2027-28 growth by a cumulative 100 BPS and inflation by 90 BPS vs Sept baseline.
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
